Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy

Murine-based CD19 CAR-T (CD19m CAR-T) therapy can lead to a relatively high CR rate when administered to B-ALL patients for the first time. However, the DOR is sub-optimal and a subset of patients even show primary resistance to CD19m CAR-T. To address these issues, we employed a humanized selective...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yu, Zhang, Jianping, Yang, Junfang, Wu, Huantong, Chen, Yao, Li, Nannan, Liu, Zhongfeng, Wang, Xuan, Liu, Weihua, Zhang, Guangji, Zhou, Bin-Bing Stephen, Lu, Peihua, Chen, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253302/
https://www.ncbi.nlm.nih.gov/pubmed/35800047
http://dx.doi.org/10.3389/fonc.2022.884782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253302/
https://www.ncbi.nlm.nih.gov/pubmed/35800047
http://dx.doi.org/10.3389/fonc.2022.884782

Ejemplares similares